Metapneumovirus strains and their use in vaccine formulations and as vectors for expression of antigenic sequences

Patent metadata

Field	Value
Publication number	US-9834824-B2
Application number	US-201715404854-A
Country	US
Kind code	B2
Filing date	Jan 12, 2017
Priority date	Feb 21, 2002
Publication date	Dec 5, 2017
Grant date	Dec 5, 2017

Abstract

Provided is an isolated mammalian negative strand RNA virus, metapneumovirus (MPV), within the sub-family Pneumoviridae, of the family Paramyxoviridae. Also provided are isolated mammalian negative strand RNA viruses identifiable as phylogenetically corresponding or relating to the genus Metapneumovirus and components thereof. In particular, provided is a mammalian MPV, subgroups and variants thereof. Also provided are genomic nucleotide sequences of different isolates of mammalian MPV, in particular, human MPV. Disclosed is the use of the sequence information of different isolates of mammalian MPV for diagnostic and therapeutic methods. Provided are nucleotide sequences encoding the genome of an MPV or a portion thereof, including both mammalian and avian MPV. Further described are chimeric or recombinant viruses encoded by the nucleotide sequences and chimeric and recombinant mammalian MPV that comprise one or more non-native or heterologous sequences. Also provided are vaccine formulations comprising mammalian or avian MPV, including recombinant and chimeric forms thereof. The vaccine preparations encompass multivalent vaccines, including bivalent and trivalent vaccine preparations.

First claim

What is claimed is:

1. A kit for determining the presence of metapneumovirus (MPV) in a mammalian subject, the kit comprising:
a DNA probe of at least 10 nucleotides that specifically hybridizes to a target polynucleotide,
wherein the DNA probe does not specifically hybridize to a polynucleotide from avian pneumovirus (APV);
wherein the probe does not hybridize under stringent conditions to a sequence encoding a polypeptide of SEQ ID NOs:366 and 368 or the complement of the sequence;
wherein the stringent conditions includes a hybridization buffer comprising 6×SSC and 1mM EDTA; and
wherein the target polynucleotide comprises a first nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:367 or the complement of the first nucleic acid; or
wherein the target polynucleotide comprises a second nucleic acid encoding a polypeptide that is at least 90% identical to SEQ ID NO:369 or the complement of the second nucleic acid.

2. The kit of claim 1 , wherein the DNA probe comprises at least 25 nucleotides.

3. The kit of claim 1 , wherein the DNA probe comprises at least 40 nucleotides.

4. The kit of claim 1 , wherein the DNA probe further comprises a detectable marker.

5. The kit of claim 1 , wherein the target polynucleotide comprises a nucleic acid encoding SEQ ID NO:367 or wherein the target polynucleotide comprises a nucleic acid encoding SEQ ID NO:369.

Assignees

• Univ Erasmus Med Ct Rotterdam

Inventors

• Fouchier Ronaldus Adrianus Maria
• Van Den Hoogen Bernadetta Gerarda
• Osterhaus Albertus Dominicus Marcellinus Erasmus
• De Jong Jan Cornelius
• Groen Jan

Classifications

• A61P31/12

  Antivirals · CPC title

• A61P31/16

  for influenza or rhinoviruses · CPC title

• A61P35/00

  Antineoplastic agents · CPC title

• A61P35/02

  specific for leukemia · CPC title

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title